Marie De Charette

Saint-pierre-les-bois, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm.

Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm.

Journal: Blood advances

Published: August 20, 2024

Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider.

Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider.

Journal: Leukemia & lymphoma

Published: December 17, 2022

Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 21, 2021

Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?

Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?

Journal: Blood advances

Published: January 26, 2021

Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 29, 2020

An 80-Year-Old Woman With a Solitary Pulmonary Nodule.

An 80-Year-Old Woman With a Solitary Pulmonary Nodule.

Journal: Chest

Published: June 17, 2019

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Journal: Haematologica

Published: February 01, 2018

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 01, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026